New serological markers in pediatric patients with inflammatory bowel disease

Table 2 Diagnostic accuracy of the combined novel antibodies with conventional serological markers in children with inflammatory bowel disease[44,45]

	Marker	Sensitivity	Specificity	PPV	NPV	Ref.
CD vs controls	ASCA	35.5%-72.8%	95.2%-96.5%	91%-93.8%	59.9%-77.8%	[44,451]
	PAB	34.0%-43.8%	100%	100%	60.2%	[44,451]
	Anti-GP2	30.2%	96%	88.3%	57.9%	[45]
	pANCA	33.0%	94.2%	85.1%	58.4%	[44]
	GAB	1.9%	98.1%	50.0%	50.0%	[44]
	PAB and/or ASCA	79.6%	95.2%	94.3%	82.3%	[44]
	Anti-GP2 and/or ASCA	50.9%	92.9%	87.8%	65.4%	[45]
	PAB and/or ASCA and/or pANCA	87.4%	89.3%	89.1%	87.6%	[44]
	PAB and /or ASCA/ pANCA-	53.4%	95.2%	91.8%	67.1%	[44]
	ASCA+/pANCA-	51.5%	95.2%	91.5%	66.2%	[44]
UC vs controls	pANCA	77.5%	94.2%	93.0%	80.9%	[44]
	GAB	12.2%	98.1%	86.5%	52.8%	[44]
	PAB	20.4%-23.5%	100%	100%	55.6%	[44,451]
	Anti-GP2	8.8%	96%	68.8%	51.3%	[45]1
	ASCA	6.9%-26.5%	95.2%-96.5%	66.3%-84.7%	50.9%-56.4%	[44,451]
	ASCA2	16.3%	95.2%	77.3%	53.2%	[44]
	PAB and/or pANCA	79.6%	94.2%	93.2%	82.2%	[44]
	PAB and/or pANCA and/or GAB	79.6%	94.2%	93.2%	82.2%	[44]
	Anti GP2 and/or ASCA	14.7%	92.9%	67.4%	52.1%	[45]
	GAB+/pANCA+	12.2%	98.1%	86.5%	52.8%	[44]
	PAB+/pANCA+	18.4%	100%	100%	55.1%	[44]
	rPAB+/pANCA+	22.4%	100%	100%	56.3%	[44]
	GAB+/PAB+/pANCA+	4.1%	100%	100%	51.0%	[44]

¹Mixed pediatric and adult cohort;

²Diagnostic value of antibodies against Saccharomyces cerevisiae (ASCA) antibodies in ulcerative colitis (UC) patients without primary sclerosing cholangitis (PSC). PAB: Pancreatic antibodies; Anti-GP2: Antibodies against glycoprotein 2; pANCA: Perinuclear anti-neutrophil cytoplasmic antibodies; GAB: Antibodies against intestinal goblet cells; IBD: Inflammatory bowel disease; CD: Crohn’s disease; PPV: Positive predictive value; NPV: Negative predictive value.